Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nefecon plus low-dose corticosteroids in high-risk primary IgA nephropathy
ChiCTR2500103994Phase 4Not yet recruiting
- Sponsor
- General Hospital of Ningxia Medical University
- Start
- Jun 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of nefecon in IgA nephropathy (IgAN), sponsored by General Hospital of Ningxia Medical University. Primary endpoint: Urine protein-to-creatinine ratio. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
nefecon
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on ChiCTR2500103994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500103994.